The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡
Open accessAbstract
One year of treatment with entecavir (0.5 mg daily) in nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) resulted in significantly improved liver histology and virological and biochemical endpoints in comparison with lamivudine. Patients who received at least 3 years of cumulative entecavir therapy in phase 3 studies and a long-term rollover study and underwent long-term liver biopsy were evaluated for improvements in histological appearance. Sixty-nine patients [50 HBeAg-positive and 19 HBeAg-negative] receiving entecavir therapy underwent long-term liver biopsy (median time of biopsy = 6 years, range = 3-7 years). Histological improvement was analyzed for 57 patients who had adequate baseline biopsy samples, baseline Knodell necroinflammatory scores ≥2, and adequate long-term biopsy samples. At the time of long-term biopsy, all patients in the cohort had a hepatitis B virus DNA level <300 copies/mL, and 86% had a normalized alanine aminotransferase level. Histological improvement (≥2-point decrease in the Knodell necroinflammatory score and no worsening of the Knodell fibrosis score) was observed in 96% of patients, and a ≥1-point improvement in the Ishak fibrosis score was found in 88% of patients, including all 10 patients with advanced fibrosis or cirrhosis at the phase 3 baseline. Conclusion: The majority of nucleoside-naive patients with CHB who were treated with entecavir in this long-term cohort achieved substantial histological improvement and regression of fibrosis or cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histological grading and staging of chronic hepatitis
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R. N. M., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,029
Knodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W., & Wollman, J. (1981) · Hepatology · doi:10.1002/hep.1840010511 · Cited by 3,522
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Self-citationPanahi, M., Naderi, M., Morteza, T. S., & Parizadeh, S. M. J. (2007) · Cited by 1,722
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
Iloeje, U. H., Yang, H., Su, J., Jen, C., You, S., & Chen, C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.016 · Cited by 1,528
Self-citationEASL clinical practice guidelines management of chronic hepatitis B
张学武, & Li, X. (2009) · Inter J Epidemiol Infect Dis · doi:10.3760/cma.j.issn.1673-4149.2009.04.001 · Cited by 1,506
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051285 · Cited by 1,444
Self-citationEASL Clinical Practice Guidelines: Management of chronic hepatitis B
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.001 · Cited by 1,347
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Lai, C.-L., Shouval, D., Lok, A. S., Chang, T.-T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051287 · Cited by 1,188
Self-citationPoynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M., & Albrecht, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.33023 · Cited by 1,146
Self-citationIredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.020 · Cited by 881
Self-citationColloredo, G., Guido, M., Sonzogni, A., & Leandro, G. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00191-0 · Cited by 869
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
Liaw, Y.-F., Leung, N., Kao, J.-H., Piratvisuth, T., Gane, E., Han, K.-H., Guan, R., Lau, G. K. K., Locarnini, S., & for the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver (2008) · Hepatology International · doi:10.1007/s12072-008-9080-3 · Cited by 867
Self-citationModels of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866
Shiratori, Y., Imazeki, F., Moriyama, M., Yano, M., Arakawa, Y., Yokosuka, O., Kuroki, T., Nishiguchi, S., Sata, M., Yamada, G., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-7-200004040-00002 · Cited by 733
Histological outcome during long-term lamivudine therapy
Dienstag, J. L., Goldin, R. D., Heathcote, E. J., Hann, H. W. L., Woessner, M., Stephenson, S. L., Gardner, S., Gray, D. F., & Schiff, E. R. (2003) · Gastroenterology · doi:10.1053/gast.2003.50013 · Cited by 726
Self-citationHepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
Yu, M.-W., Yeh, S.-H., Chen, P.-J., Liaw, Y.-F., Lin, C.-L., Liu, C.-J., Shih, W.-L., Kao, J.-H., Chen, D.-S., & Chen, C.-J. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji043 · Cited by 569
Self-citationHammel, P., Couvelard, A., O'Toole, D., Ratouis, A., Sauvanet, A., Fléjou, J. F., Degott, C., Belghiti, J., Bernades, P., Valla, D., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102083440604 · Cited by 427
The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis
Elsharkawy, A. M., Oakley, F., & Mann, D. A. (2005) · Apoptosis · doi:10.1007/s10495-005-1055-4 · Cited by 419
Issa, R., Williams, E., Trim, N., Kendall, T., Arthur, M. J. P., Reichen, J., Benyon, R. C., & Iredale, J. P. (2001) · Gut · doi:10.1136/gut.48.4.548 · Cited by 319
Marcellin, P., Chang, T.-T., Lim, S. G. L., Sievert, W., Tong, M., Arterburn, S., Borroto-Esoda, K., Frederick, D., & Rousseau, F. (2008) · Hepatology · doi:10.1002/hep.22414 · Cited by 306
Self-citationMommeja-Marin, H., Mondou, E., Blum, R. M., & Rousseau, F. (2003) · Hepatology · doi:10.1053/jhep.2003.50208 · Cited by 275
Chen, G., Lin, W., Shen, F., Iloeje, U. H., London, W. T., & Evans, A. A. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00647.x · Cited by 275
Self-citationBENYON, R. C., & IREDALE, J. P. (2000) · Gut · doi:10.1136/gut.46.4.443 · Cited by 262
Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection
Iloeje, U. H., Yang, H., Jen, C., Su, J., Wang, L., You, S., & Chen, C. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.06.015 · Cited by 230
Self-citationLeung, N., Peng, C., Hann, H., Sollano, J., Lao‐Tan, J., Hsu, C., Lesmana, L., Yuen, M., Jeffers, L., Sherman, M., et al. (2009) · Hepatology · doi:10.1002/hep.22658 · Cited by 182
Regression of Hepatic Fibrosis in Hepatitis C with Long-Term Interferon Treatment
Dufour, J., Delellis, R., & Kaplan, M. M. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1026601904609 · Cited by 114
Manolakopoulos, S., Triantos, C. K., Theodoropoulos, J., Vlachogiannakos, J., Kougioumtzan, A., Papatheodoridis, G., Tzourmakliotis, D., Karamanolis, D. G., Burroughs, A. K., Archimandritis, A. J., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.031 · Cited by 110
Reversibility of Cirrhosis in Patients Cured of Thalassemia by Bone Marrow Transplantation
Muretto, P., Angelucci, E., & Lucarelli, G. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-9-200205070-00009 · Cited by 102
Reversibility of cirrhosis in chronic hepatitis B
Malekzadeh, R., Mohamadnejad, M., Rakhshani, N., Nasseri‐Moghaddam, S., Merat, S., Tavangar, S. M., & Sohrabpour, A. A. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00066-7 · Cited by 54
α-Interferon Improves Liver Fibrosis in Chronic Hepatitis C
Serejo, F., Costa, A., Oliveira, A. G., Ramalho, F. J., Batista, A., & de Moura, M. C. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1010649403659 · Cited by 23
Han, S. B., Chang, T., Chao, Y., Yoon, S.-K., Gish, R. G., Cheinquer, H., Kitis, G. E., Zhang, H., & Iloeje, U. H. (2009) · Cited by 13
Self-citation
Cited by
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citationAASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Metadata
- Authors
- Chang, T.-T., Liaw, Y.-F., Wu, S.-S., Schiff, E., Han, K.-H., Lai, C.-L., Safadi, R., Lee, S. S., Halota, W., Goodman, Z., Chi, Y.-C., Zhang, H., Hindes, R., Iloeje, U., Beebe, S., & Kreter, B.
- Venue
- Hepatology
- Published
- 2010-09
- Volume
- 52
- Issue
- 3
- Pages
- 886-893
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1964491003
- Cited by
- 972
- References
- 36
- FWCI
- 37.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.